Elucida Oncology Closes $44 Million Series A-1 Financing
Elucida Oncology Closes $44 Million Series A-1 Financing Elucida Oncology Closes $44 Million Series A-1 Financing MONMOUTH JUNCTION, N.J., Jan. 12, 2021 — Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today it has closed a $44 million Series A-1 financing. “Over the past two years, Elucida Oncology has successfully evolved to forge two paths in the world of precision oncology with its proprietary C’Dot platform. As our collaborators at leading research institutions continue to push the boundary of C’Dots’ potential in d...